Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| plasmacytoid dendritic cell | 9 studies | 23% ± 5% | |
| plasma cell | 8 studies | 36% ± 14% | |
| natural killer cell | 7 studies | 20% ± 6% | |
| fibroblast | 7 studies | 22% ± 11% | |
| conventional dendritic cell | 6 studies | 30% ± 16% | |
| ciliated cell | 6 studies | 29% ± 8% | |
| mast cell | 6 studies | 21% ± 6% | |
| B cell | 5 studies | 24% ± 9% | |
| plasmablast | 5 studies | 34% ± 18% | |
| non-classical monocyte | 4 studies | 27% ± 9% | |
| endothelial cell | 4 studies | 27% ± 10% | |
| epithelial cell | 4 studies | 45% ± 14% | |
| retina horizontal cell | 4 studies | 24% ± 11% | |
| macrophage | 4 studies | 26% ± 9% | |
| basal cell | 4 studies | 33% ± 14% | |
| pancreatic A cell | 3 studies | 30% ± 8% | |
| classical monocyte | 3 studies | 29% ± 13% | |
| smooth muscle cell | 3 studies | 16% ± 1% | |
| hematopoietic stem cell | 3 studies | 17% ± 3% | |
| pericyte | 3 studies | 20% ± 4% | |
| retinal rod cell | 3 studies | 24% ± 7% | |
| dendritic cell | 3 studies | 35% ± 16% | |
| innate lymphoid cell | 3 studies | 20% ± 5% | |
| goblet cell | 3 studies | 23% ± 4% | |
| intestinal crypt stem cell | 3 studies | 19% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 1676.78 | 1445 / 1445 | 100% | 9.83 | 183 / 183 |
| ovary | 100% | 1196.78 | 180 / 180 | 100% | 10.44 | 430 / 430 |
| pancreas | 100% | 1598.80 | 328 / 328 | 100% | 11.52 | 178 / 178 |
| uterus | 100% | 1690.98 | 170 / 170 | 100% | 12.93 | 459 / 459 |
| thymus | 100% | 1451.52 | 653 / 653 | 100% | 12.20 | 604 / 605 |
| bladder | 100% | 1760.29 | 21 / 21 | 100% | 13.27 | 503 / 504 |
| prostate | 100% | 1881.96 | 245 / 245 | 100% | 12.80 | 501 / 502 |
| breast | 100% | 1732.22 | 459 / 459 | 100% | 17.82 | 1115 / 1118 |
| kidney | 100% | 1496.24 | 89 / 89 | 100% | 8.76 | 898 / 901 |
| lung | 100% | 1523.26 | 576 / 578 | 100% | 9.55 | 1155 / 1155 |
| adrenal gland | 100% | 1775.82 | 258 / 258 | 100% | 10.79 | 229 / 230 |
| liver | 100% | 1225.00 | 225 / 226 | 100% | 10.91 | 406 / 406 |
| brain | 100% | 1482.96 | 2634 / 2642 | 100% | 10.16 | 704 / 705 |
| stomach | 100% | 1304.21 | 359 / 359 | 99% | 9.24 | 284 / 286 |
| intestine | 100% | 1956.13 | 966 / 966 | 99% | 9.80 | 523 / 527 |
| skin | 100% | 2001.84 | 1809 / 1809 | 97% | 7.72 | 458 / 472 |
| adipose | 100% | 1485.67 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 22.88 | 29 / 29 |
| spleen | 100% | 2169.00 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 10.28 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 14.14 | 1 / 1 |
| muscle | 100% | 1943.32 | 802 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1651.89 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 1874.11 | 852 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 94% | 6.25 | 75 / 80 |
| peripheral blood | 80% | 1032.69 | 747 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006814 | Biological process | sodium ion transport |
| GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005634 | Cellular component | nucleus |
| GO_0005515 | Molecular function | protein binding |
| Gene name | COMMD3 |
| Protein name | Polycomb complex protein BMI-1 (Polycomb group RING finger protein 4) COMM domain-containing protein 3 COMM domain-containing protein 3 (Protein Bup) (Protein PIL) COMM domain containing 3 |
| Synonyms | C10orf8 BUP |
| Description | FUNCTION: May modulate activity of cullin-RING E3 ubiquitin ligase (CRL) complexes . May down-regulate activation of NF-kappa-B . Modulates Na(+) transport in epithelial cells by regulation of apical cell surface expression of amiloride-sensitive sodium channel (ENaC) subunits . . |
| Accessions | R4GN06 Q6IB93 ENST00000448361.5 ENST00000376836.8 Q9UBI1 H0Y6Z9 H0Y4E5 H0Y4W0 ENST00000444869.5 ENST00000471350.1 ENST00000456711.5 R4GNF2 ENST00000472610.5 |